ACM
CCCC icon

ADAR1 Capital Management’s C4 Therapeutics CCCC Stock Holding History

ADAR1 Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Buy
291,957
+248,957
+579% +$852K 0.06% 154
2026
Q1 		$113K Buy
+43,000
New +$101K 0.01% 285

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

ADAR1 Capital Management's CCCC Position: Q2 2026 in Review

ADAR1 Capital Management increased its C4 Therapeutics (CCCC) stake by 579% in Q2 2026, buying an estimated $852K and bringing the position to 291,957 shares worth $1.36M. The position accounts for 0.06% of the portfolio, ranked #154.

ADAR1 Capital Management first reported a position in CCCC in Q1 2026 and has held it in 2 quarters since. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • ADAR1 Capital Management held 291,957 shares of C4 Therapeutics worth $1.36M as of Q2 2026.
  • ADAR1 Capital Management bought 248,957 C4 Therapeutics shares in Q2 2026, an estimated $852K.
  • C4 Therapeutics made up 0.06% of ADAR1 Capital Management's portfolio in Q2 2026, its #154 holding.
  • ADAR1 Capital Management first reported a position in C4 Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.